

1646 \$



Attorney Docket No.: 3985.240-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Havelund et al.

RECEIVED

Serial No.: 09/398,365

Group Art Unit: 1646

JUN 13 2002

Filed: September 17, 1999

Examiner: C. Saoud

TECH CENTER 1600,2900

Confirmation No: 9987

For: Acylated Insulin

CERTIFICATE OF MAILING UNDER 37 CFR 1.8(a)

Commissioner for Patents  
Washington, DC 20231

Sir:

I hereby certify that the attached correspondence comprising:

1. Information Disclosure Statement
2. Form PTO-1449
3. Copy of References (2 Total)

is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Commissioner for Patents  
Washington, DC 20231

on May 29, 2002.

Sylvia Gonzalez  
(name of person mailing paper)

[Signature]  
(signature of person mailing paper)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



In re Application of: Havelund et al.

Application No.: 09/398,365

Group Art Unit: 1646

Filed: September 17, 1999

Examiner: C. Saoud

Confirmation No: 9987

For: Acylated Insulin

RECEIVED  
JUN 13 2002  
TECH CENTER 101-2800

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents  
Washington, DC 20231

Sir:

In accordance with 37 C.F.R. 1.56, 1.97 and 1.98, Applicants submit herewith references which they believe may be material to the patentability of this application and with respect to which there may be a duty to disclose in accordance with 37 C.F.R. 1.56.

While the references may be "material" under 37 C.F.R. 1.56, it is not intended to constitute an admission that the references are "prior art" unless specifically designated as such.

The filing of this Supplemental Information Disclosure Statement shall not be construed as a representation that no material references other than those listed exist or that a search has been conducted.

The references are listed in Form PTO-1449 which is in accordance with the requirements of M.P.E.P. 609. A copy of the references is also enclosed.

The references are as follows:

1. U.S. 3,868,357
2. U.S. 3,907,763

record therein. The Examiner is also invited to contact the Undersigned if there are any questions concerning this paper or the attached references.


This Supplemental Information Disclosure statement is being filed **after** the period set forth in 37 C.F.R. 1.97(b), but **before** the mailing date of any of a final action, a notice of allowance, or an action that otherwise closes prosecution.

Accompanying this information disclosure statement is:

☒ the fee set forth in 37 C.F.R. § 1.17(p) (currently \$180.00). Charge Deposit Account No. 14-1447 in the amount of \$180.00. A duplicate of this charge directive is attached.

Respectfully submitted,

Date: May 29, 2002

  
Richard W. Bork, Reg. No. 36,459  
Novo Nordisk of North America, Inc.  
405 Lexington Avenue, Suite 6400  
New York, NY 10174-6401  
(212) 867-0123



23650

PATENT TRADEMARK OFFICE